Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Capecitabine

FDA-approved product (tablet, oral), marketed as Capecitabine, Xeloda.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Capecitabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Actinic keratosis
  • Adenocarcinoma
  • Basal cell carcinoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Colon carcinoma
  • Colonic neoplasm
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal neoplasm
  • Gastric adenocarcinoma
  • Gastric cancer
  • Gastric carcinoma
  • and 6 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Pyrimidine analogues
FDA pharmacologic class
Nucleoside Metabolic Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Capecitabine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Capecitabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Trial of Using SIB-IMRT in Preoperative Radiotherapy for Locally Advanced Rectum Cancer

    NCT02195141 · start 2014-01

    Registered record
    Registry ID
    NCT02195141
    Conditions
    Rectal Cancer
    Interventions
    conventional fraction; SIB
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2015-12
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRectal Cancer
    Interventionconventional fraction; SIB
    PhasePhase 2
    Registry statusUnknown

  • A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

    NCT01808573 · start 2013-03-29

    Registered record
    Registry ID
    NCT01808573
    Conditions
    HER2+ Metastatic Breast Cancer (MBC)
    Interventions
    neratinib; capecitabine; lapatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03-29
    Completion
    2019-12-09
    Enrolment
    621

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2+ Metastatic Breast Cancer (MBC)
    Interventionneratinib; capecitabine; lapatinib
    PhasePhase 3
    Registry statusCompleted

  • A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors

    NCT02025803 · start 2012-11

    Registered record
    Registry ID
    NCT02025803
    Conditions
    Neoplasms
    Interventions
    TAS-114/capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-11
    Completion
    2017-07-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionTAS-114/capecitabine
    PhasePhase 1
    Registry statusCompleted

  • Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer

    NCT01359397 · start 2011-03

    Registered record
    Registry ID
    NCT01359397
    Conditions
    Metastatic Gastric Cancer; Adenocarcinoma of the Gastro-oesophageal Junction
    Interventions
    Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab; Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-03
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Gastric Cancer; Adenocarcinoma of the Gastro-oesophageal Junction
    InterventionDocetaxel, Oxaliplatin, Capecitabin, Bevacizumab; Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
    PhasePhase 2
    Registry statusUnknown

  • Metronomic Therapy in Metastatic Breast Cancer.

    NCT01131195 · start 2010-07-19

    Registered record
    Registry ID
    NCT01131195
    Conditions
    Breast Cancer
    Interventions
    bevacizumab, Paclitaxel; Bevacizumab, Cyclophosphamide, Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-07-19
    Completion
    2018-02-28
    Enrolment
    139

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionbevacizumab, Paclitaxel; Bevacizumab, Cyclophosphamide, Capecitabine
    PhasePhase 3
    Registry statusCompleted

  • Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

    NCT01126138 · start 2010-07

    Registered record
    Registry ID
    NCT01126138
    Conditions
    Carcinoma, Invasive Ductal, Breast
    Interventions
    Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine; Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2010-07
    Completion
    2015-08
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Invasive Ductal, Breast
    InterventionVinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine; Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
    PhasePhase 3
    Registry statusUnknown

  • Additional Chemotherapy After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer

    NCT01671683 · start 2010-07

    Registered record
    Registry ID
    NCT01671683
    Conditions
    Rectal Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-07
    Completion
    2011-09
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRectal Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

    NCT01369433 · start 2010-06

    Registered record
    Registry ID
    NCT01369433
    Conditions
    Solid Tumors
    Interventions
    Tivozanib + paclitaxel; Tivozanib + temsirolimus; Tivozanib; Tivozanib (AV-951); Tivozanib + capecitabine; Tivo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2010-06
    Completion
    2015-10
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionTivozanib + paclitaxel; Tivozanib + temsirolimus; Tivozanib; Tivozanib (AV-951) +2 more
    PhaseNot applicable
    Registry statusTerminated

  • Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease

    NCT01387295 · start 2010-04

    Registered record
    Registry ID
    NCT01387295
    Conditions
    Metastatic Breast Cancer; Liver Metastases
    Interventions
    oxaliplatin, capecitabine, trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-04
    Completion
    2017-09-01
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer; Liver Metastases
    Interventionoxaliplatin, capecitabine, trastuzumab
    PhasePhase 2
    Registry statusCompleted

  • Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors

    NCT00726687 · start 2008-06

    Registered record
    Registry ID
    NCT00726687
    Conditions
    Advanced Solid Tumors
    Interventions
    indibulin; capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2008-06
    Completion
    2013-06
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    Interventionindibulin; capecitabine
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment

    NCT00809796 · start 2008-03

    Registered record
    Registry ID
    NCT00809796
    Conditions
    Colorectal Cancer
    Interventions
    pentamidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2008-03
    Completion
    2011-06
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionpentamidine
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

    NCT00496587 · start 2007-07

    Registered record
    Registry ID
    NCT00496587
    Conditions
    Renal Cell Carcinoma; Kidney Cancer
    Interventions
    Capecitabine; Gemcitabine; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-07
    Completion
    2016-05
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma; Kidney Cancer
    InterventionCapecitabine; Gemcitabine; Bevacizumab
    PhasePhase 2
    Registry statusCompleted

  • Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

    NCT00408408 · start 2006-11

    Registered record
    Registry ID
    NCT00408408
    Conditions
    Breast Cancer
    Interventions
    bevacizumab; capecitabine; cyclophosphamide; docetaxel; doxorubicin hydrochloride (Adriamycin); gemcitabine hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-11
    Completion
    2018-03
    Enrolment
    1,206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionbevacizumab; capecitabine; cyclophosphamide; docetaxel +2 more
    PhasePhase 3
    Registry statusUnknown

  • Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma

    NCT00681798 · start 2006-07

    Registered record
    Registry ID
    NCT00681798
    Conditions
    Pancreatic Cancer
    Interventions
    Vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-07
    Completion
    2009-06
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionVandetanib
    PhasePhase 1
    Registry statusCompleted

  • Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma

    NCT02240771 · start 2006-01

    Registered record
    Registry ID
    NCT02240771
    Conditions
    Hepatocellular Carcinoma
    Interventions
    Transarterial chemotherapy; Oral chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2006-01
    Completion
    2015-03
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionTransarterial chemotherapy; Oral chemotherapy
    PhasePhase 2 / Phase 3
    Registry statusUnknown